Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tooth whitener safety

This article was originally published in The Tan Sheet

Executive Summary

Canadian researchers determine tooth-whitening products with hydrogen peroxide or carbamide peroxide do not increase users' risks for oral cancers, including people who abuse alcohol and/or are heavy smokers. The review of study literature, including unpublished studies with tests involving more than 4,000 people, was conducted by Ian Munro, PhD, associate director of the University of Toronto's Program in Food, Safety & Regulatory Affairs, et al., and published in the Journal of Esthetic & Restorative Dentistry, according to a Nov. 16 release. Exposures to hydrogen peroxide, which generally is the effective ingredient in tooth whiteners, are too low and, at 30 to 60 minutes, too brief to increase risks for oral cancer, the study results show. Concentrations of the substance quickly diminish to be nearly undetectable within 15 to 60 minutes. In March 2005, a European Union's Scientific Committee on Consumer Products 1opinion raised concerns about the safety of products containing the ingredients. In Europe, tooth whitening products with hydrogen peroxide or carbamide peroxide are only available to consumers from a dental practitioner, Munro et al. note...

You may also be interested in...

Shine More Safety Data On Tooth Whiteners With Hydrogen Peroxide – SCCP

The use of oral hygiene products and tooth whitening products containing more than 0.1 percent hydrogen peroxide cannot be deemed safe in the absence of long-term clinical data assessing possible adverse effects within the oral cavity, the European Commission's science panel says

Coronavirus Update: US Public Confidence In COVID-19 Vaccines Declines

Confidence in the vaccine has slipped in the US, regardless of political affiliation.

Janssen’s Amivantamab Combo Shows Promise In First-Line NSCLC

Janssen presents highly encouraging interim results at ESMO from the CHRYSALIS study with a combination of amivantamab and lazertinib. Based on the data, the global Phase III MARIPOSA study, which will assess the combo versus blockbuster Tagrisso, will begin next month including in South Korea, home to lazertinib's originator. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts